Myriad Genetics Inc
MYGN
View Detailed Chart
4.680USD
+0.070+1.52%
Close 03/25, 16:00（ET）Quotes delayed by 15 min
396.07MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.52%
5 Days
+0.86%
1 Month
-2.09%
6 Months
-39.69%
Year to Date
-23.90%
1 Year
-51.90%
View Detailed Chart
TradingKey Stock Score of Myriad Genetics Inc
Currency: USD Updated: 2026-03-25Key Insights
Myriad Genetics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 76 out of 209 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 7.39.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Myriad Genetics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Myriad Genetics Inc Highlights
StrengthsRisks
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 824.50M.
Overvalued
The company’s latest PE is -1.18, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 93.01M shares, decreasing 12.01% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 31.35K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.07.
Analyst Rating
Based on
13
analysts
Hold
Current Rating
7.391
Target Price
+58.60%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Myriad Genetics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Myriad Genetics Inc Info
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Ticker SymbolMYGN
CompanyMyriad Genetics Inc
CEORaha (Samraat S)
Websitehttps://myriad.com/
Related Instruments
-0.64%
-0.35%
+0.10%
-0.41%
+0.74%
-1.55%
-0.26%
+2.39%
+1.98%
-0.85%
+1.51%
-0.67%
+1.69%
+0.97%
+1.20%
+1.52%
-1.07%
+1.37%
-0.82%
+1.51%Popular Symbols
252.620
+0.980 (+0.39%)
178.680
+3.480 (+1.99%)
69631.460
-1348.040 (-1.90%)
296.140
-4.910 (-1.63%)
2080.410
-83.580 (-3.86%)
385.950
+2.920 (+0.76%)
4441.480
-63.960 (-1.42%)
92.452
+1.513 (+1.66%)
1.156
+0.000 (+0.03%)
159.449
-0.010 (-0.01%)
